Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation company, today announced that initial Phase 1 clinical results with PLX-4545, a selective IKZF2 molecular glue degrader, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback